Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Broncus Holding's Enterprise Value is HK$-211.98 Mil.
Broncus Holding's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-118.57 Mil. Therefore, Broncus Holding's EV-to-EBIT ratio for today is 1.79.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Broncus Holding's Enterprise Value is HK$-211.98 Mil.
Broncus Holding's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-105.07 Mil. Therefore, Broncus Holding's EV-to-EBITDA ratio for today is 2.02.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Broncus Holding's Enterprise Value is HK$-211.98 Mil.
Broncus Holding's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was HK$63.34 Mil. Therefore, Broncus Holding's EV-to-Revenue ratio for today is -3.35.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Broncus Holding's Enterprise Value is HK$-211.98 Mil.
Broncus Holding's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-155.63 Mil. Therefore, Broncus Holding's EV-to-FCF ratio for today is 1.36.
Broncus Holding Enterprise Value Historical Data
The historical data trend for Broncus Holding's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Broncus Holding's Enterprise Value
For the Medical Devices subindustry, Broncus Holding's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Broncus Holding's Enterprise Value Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Broncus Holding's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Broncus Holding's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Broncus Holding's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Broncus Holding (HKSE:02216) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Broncus Holding's current Enterprise Value is HK$-211.98 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Broncus Holding's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-118.57 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Broncus Holding's current Enterprise Value is HK$-211.98 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Broncus Holding's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-105.07 Mil.
Broncus Holding's current Enterprise Value is HK$-211.98 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Broncus Holding's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was HK$63.34 Mil.
Broncus Holding's current Enterprise Value is HK$-211.98 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Broncus Holding's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was HK$-155.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Broncus Holding Enterprise Value Related Terms
Thank you for viewing the detailed overview of Broncus Holding's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Broncus Holding Corp is a medical device company focused on the development of interventional pulmonology products. It is engaged in the field of interventional pulmonology, providing lung solutions in China and globally. The integrated interventional pulmonology platform addresses the pain points of the existing diagnosis and treatment paradigms and unmet medical needs for lung diseases by improving the diagnosis and treatment effects of lung cancer and COPD. The company offers products like Archimedes System, LungPoint, BioStar, FleXNeedle Biopsy Needle, RF-II, and InterVapor System among others. Geographically, the company derives a majority of its revenue from the Chinese Mainland, and the rest from European Union, USA, and other regions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02216 has been successfully added to your 